Findings

What do systematic reviews say?

4,815 questions · 6,211 findings · 638 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1,052 · 16.9%GRADE not reported 441 · 7.1%Very low 1,700 · 27.4%Low 1,651 · 26.6%Moderate 1,070 · 17.2%High 297 · 4.8%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

Clearing or excellent improvement · people with discoid lupus erythematosus

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 10 participants
GRADE not reported

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

At least 50% reduction in erythema · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

Quality of life measure · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

Relapse · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

1% pimecrolimus cream vs betamethasone 17‐valerate 0.1%

Adverse events of medication, leading to discontinuation or significant morbidity · people with discoid lupus erythematosus

The review found no eligible studies for this question.

1 finding from 1 review

Drugs for discoid lupus erythematosus 2017 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Bisphosphonates vs placebo/observation

Median time to a skeletal‐related event · women with advanced breast cancer without bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 73 participants
Low

Bisphosphonates vs placebo/observation

Overall survival · women with advanced breast cancer without bone metastases

Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 0.89 [0.73, 1.09]
3 studies · 330 participants
High

Bisphosphonates vs placebo/observation

Quality of life · women with advanced breast cancer without bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 124 participants
Moderate

Bisphosphonates vs placebo/observation

Skeletal‐related event (SRE) · women with metastatic breast cancer with bone metastases

Bisphosphonates leads to lower skeletal‐related event (SRE) compared with placebo/observation (high certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 0.86 [0.78, 0.95]
9 studies · 2810 participants
High

Bisphosphonates vs placebo/observation

Median time to a skeletal‐related event · women with metastatic breast cancer with bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
9 studies · 2891 participants
High

Bisphosphonates vs placebo/observation

Overall survival · women with metastatic breast cancer with bone metastases

Bisphosphonates showed no clear difference in overall survival compared with placebo/observation (moderate certainty).

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
RR 1.01 [0.91, 1.11]
7 studies · 1935 participants
Moderate

Bisphosphonates vs placebo/observation

Bone pain · women with metastatic breast cancer with bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 3297 participants
Moderate

Bisphosphonates vs placebo/observation

Quality of life · women with metastatic breast cancer with bone metastases

1 finding from 1 review

Bisphosphonates and other bone agents for breast cancer 2017 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1888 participants
Moderate

Hearing loss prevention programme vs audiometric testing (hearing loss)

Hearing loss STS ≥ 10 dB hearing loss average over 2, 3, 4 kHz in either ear · agricultural students without hearing loss

Hearing loss prevention programme showed no clear difference in hearing loss STS ≥ 10 dB loss average over 2, 3, 4 kHz in either ear compared with audiometric testing (hearing loss) (moderate certainty).

2 findings from 1 review

Interventions to prevent occupational noise‐induced hearing loss 2017 · Cochrane Headline outcomes only
OR 0.85 [0.29, 2.44]
1 study · 687 participants
Moderate
Interventions to prevent occupational noise‐induced hearing loss 2017 · Cochrane Headline outcomes only
OR 0.94 [0.46, 1.91]
1 study · 355 participants
Moderate

Oral vs intravenous fluoropyrimidines

Grade ≥ 3 neutropenia/granulocytopenia · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy

Oral may leads to lower grade ≥ 3 neutropenia/granulocytopenia compared with intravenous fluoropyrimidines (low certainty).

1 finding from 1 review

Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
OR 0.17 [0.15, 0.18]
29 studies · 11794 participants
Low

Oral vs intravenous fluoropyrimidines

Progression‐free survival · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy

Oral probably leads to higher progression‐free survival compared with intravenous fluoropyrimidines (moderate certainty).

1 finding from 1 review

Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.06 [1.02, 1.11]
23 studies · 9927 participants
Moderate

Oral vs intravenous fluoropyrimidines

Overall survival · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy

Oral showed no clear difference in overall survival compared with intravenous fluoropyrimidines (high certainty).

1 finding from 1 review

Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
HR 1.02 [0.99, 1.05]
29 studies · 12079 participants
High

Oral vs intravenous fluoropyrimidines

Grade ≥ 3 diarrhoea · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy

Oral may leads to higher grade ≥ 3 diarrhoea compared with intravenous fluoropyrimidines (low certainty).

1 finding from 1 review

Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
OR 1.66 [1.5, 1.84]
30 studies · 11997 participants
Low

Oral vs intravenous fluoropyrimidines

Hand‐foot syndrome (grade ≥ 3) · Patients treated with palliative intent for inoperable advanced or metastatic colorectal cancer with chemotherapy

Oral probably leads to higher grade ≥ 3 hand foot syndrome compared with intravenous fluoropyrimidines (moderate certainty).

1 finding from 1 review

Oral versus intravenous fluoropyrimidines for colorectal cancer 2017 · Cochrane Headline outcomes only
OR 3.92 [2.84, 5.43]
18 studies · 6481 participants
Moderate

HALOPERIDOL vs COMBINATIONS: c. HALOPERIDOL + PROMETHAZINE

Tranquillisation or asleep · psychosis‐induced aggression or agitation

HALOPERIDOL probably leads to higher tranquillisation or asleep compared with COMBINATIONS: d. HALOPERIDOL + PROMETHAZINE (moderate certainty).

1 finding from 1 review

Haloperidol for psychosis‐induced aggression or agitation (rapid tranquillisation) 2017 · Cochrane Headline outcomes only
RR 1.6 [1.18, 2.16]
1 study · 316 participants
Moderate